TJ-M2010-5, a novel CNS drug candidate, attenuates acute cerebral ischemia-reperfusion injury through the MyD88/NF-κB and ERK pathway.
TJ-M2010-5, a novel CNS drug candidate, attenuates acute cerebral ischemia-reperfusion injury through the MyD88/NF-κB and ERK pathway.
复制标题
TJ-M2010-5是一种新的中枢神经系统候选药物,通过MyD88/NF-κB和ERK通路减轻急性脑缺血再灌注损伤。
DOI:
10.3389/fphar.2022.1080438
复制
发表时间:
2022
影响因子:
5.6
通讯作者:
Zhou, Ping
中科院分区:
文献类型:
--
作者:
Li, Zeyang;Zhao, Minghui;Zhang, Xiaoqian;Lu, Yiran;Yang, Yang;Xie, Yalong;Zou, Zhimiao;Zhou, Liang;Shang, Runshi;Zhang, Limin;Jiang, Fengchao;Du, Dunfeng;Zhou, Ping
Background: Cerebral ischemia-reperfusion injury (CIRI) inevitably occurs after vascular recanalization treatment for ischemic stroke. The accompanying inflammatory cascades have a major impact on outcome and regeneration after ischemic stroke. Evidences have demonstrated that TLR/MyD88/NF-κB signaling contributes to CIRI. This study aimed to investigate the druggability of MyD88 in the central nervous system (CNS) and the neuroprotective and anti-neuroinflammatory effects of the MyD88 inhibitor TJ-M2010-5 on CIRI. Methods: A middle cerebral artery occlusion (MCAO) model was used to simulate CIRI in mice. BV-2 cells were stimulated with oxygen glucose deprivation/reoxygenation (OGD/R) or lipopolysaccharide, and SH-SY5Y cells were induced by OGD/R in vitro. Neurological deficit scores and cerebral infarction volumes were evaluated. Immunofluorescence staining was performed to measure neuronal damage and apoptosis in the brain. The anti-neuroinflammatory effect of TJ-M2010-5 was evaluated by analyzing the expression of inflammatory cytokines, activation of microglia, and infiltration of peripheral myeloid cells. The expression of proteins of the MyD88/NF-κB and ERK pathway was detected by Simple Western. The concentrations of TJ-M2010-5 in the blood and brain were analyzed by liquid chromatography-mass spectrometry. Results: The cerebral infarction volume decreased in mice treated with TJ-M2010-5, with the most prominent decrease being approximately 80% of the original infarction volume. Neuronal loss and apoptosis were reduced following TJ-M2010-5 treatment. TJ-M2010-5 inhibited the infiltration of peripheral myeloid cells and the activation of microglia. TJ-M2010-5 also downregulated the expression of inflammatory cytokines and inhibited the MyD88/NF-κB and ERK pathway. Furthermore, TJ-M2010-5 showed good blood-brain barrier permeability and no neurotoxicity. Conclusion: TJ-M2010-5 has an excellent therapeutic effect on CIRI as a novel CNS drug candidate by inhibiting excessive neuroinflammatory responses.
登录
查看更多内容
影响因子:
5.3
作者:
Cheng, Man;Yang, Liu;Zhang, Xumei
通讯作者:
Zhang, Xumei
DOI:
10.2147/dddt.s267856
发表时间:
2021
期刊:
Drug design, development and therapy
影响因子:
--
作者:
Dong X;Wang L;Song G;Cai X;Wang W;Chen J;Wang G
通讯作者:
Wang G
影响因子:
7.5
作者:
Gao, Yin;Fang, Xiubin;Zhang, Baohui
通讯作者:
Zhang, Baohui
影响因子:
29.4
作者:
Liu, Yu;Hu, Ping;Wang, Xiaolei
通讯作者:
Wang, Xiaolei
影响因子:
30.5
作者:
Liu, Qingkun;Johnson, Emily M.;Andreasson, Katrin I.
通讯作者:
Andreasson, Katrin I.